Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats...

cafead

Administrator
Staff member
  • cafead   Jun 22, 2021 at 11:02: PM
via As Bristol Myers Squibb looks to guard Celgene’s top-selling cancer drug Revlimid from copycat competition, the company has inked a series of deals to welcome generic challengers in waves. India’s Sun Pharmaceutical is the latest to get in on the action.

article source